BRAF as a potential therapeutic target in melanoma and other malignancies.
about
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cellsSynergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor RapamycinPreponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastasesCurrent and future trials of targeted therapies in cutaneous melanomaAn Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase InhibitorsA Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf InhibitorsBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?Melanoma genetics and the development of rational therapeutics.Comprehensive mapping of the human kinome to epidermal growth factor receptor signalingZebrafish models of p53 functions.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesMolecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapyArsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway.Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.Targeting sphingosine kinase-1 to inhibit melanoma.Targeting the mitogen-activated protein kinase cascade to treat cancer.Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathwayApplication of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.UV-induced skin cancer: similarities--variations.Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro.Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancerSelective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.DNA methylation and cancer pathways in gastrointestinal tumors.Use of liposomes as drug delivery vehicles for treatment of melanoma.Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastasesImmunoediting of leukocyte functions within the tumor microenvironment promotes cancer metastasis development.Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules.Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development.Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.Vemurafenib in melanoma.BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.Specifically targeting ERK1 or ERK2 kills melanoma cellsSPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
P2860
Q24602021-3B152A5E-6A9B-460F-BB01-AB3AB57A4852Q24811525-97286853-1E0D-4AE0-856A-171BC4F188A2Q24814098-63AC08E2-49BF-4B1E-90E5-A009D4D1C7E3Q27022355-006118C3-FD1E-4FE4-860E-26A39F2D0FC2Q28607031-657F703D-04B3-4B4E-9668-67046A1C1990Q28647625-0A771306-B885-4D93-A985-9DC94B3D532CQ30458424-60648F4D-ECB1-4446-8068-06E306B99235Q33517983-81563378-B574-44CE-9516-8686BB70203BQ33726956-3952DAE5-9942-4B7B-AEDC-3E1E132E323CQ33966943-8B9E76C9-9648-49DF-9270-7EBE34FC11DDQ34014685-A961FD6C-63CB-468D-90C8-F1602100B20BQ34639532-B9AFFF4E-AEF8-45D5-A60D-0F51923F5AA3Q35118157-2F62FC8C-3F4A-4C6F-92F5-652D2B274AD8Q35320386-8D1F3681-F6AB-44A3-A17F-BEC68AE872FCQ35581006-D09BB88D-7C24-477B-89B5-A09A9590A8D0Q35598807-030448B3-3EAC-4FE7-B7B0-063FCFEC7E7AQ35789935-979E2004-C75A-4355-9255-48636E9B1DAEQ35968411-BAE02B85-A6C7-4825-89D4-715DF37D16E5Q35981512-CF3215CA-3979-42DA-9AA0-B0D8C39EA0D2Q35988122-84FDB374-0B01-482C-947A-D1AA317DAEABQ36020990-D0F460F5-2239-4196-BBCE-9A9CFD2C98D2Q36168638-57310268-ED7F-497B-91C8-863215DBE695Q36336131-3D531B98-5D5C-4638-8341-64EE10BBC3C7Q36818078-C2F54B07-A4B3-4E5B-AF08-57FE21D98A28Q36961746-9F52714A-2055-41ED-95A2-78B7D8B0AE24Q37270522-D0B09A33-D03C-4229-9F4E-8242EAD284C7Q37274568-DA5D0D80-9979-4459-860C-EC64BFCB8544Q37346219-2C65C889-5C7A-4395-817A-29AC56CC9841Q37406217-21123980-1E5A-4970-817A-D15017B2C868Q37421620-42614073-6F0D-4BA6-A174-A4B80B841C57Q37421628-73AD8133-5FFB-40A2-8D31-B8E3A4F05650Q37431090-F3EAC6B2-26CB-48F3-A33F-C66A7B817010Q37627169-2FE8DAF6-B7D9-40A7-BF8C-052F7F52BF11Q37745182-E6234C6D-64ED-484E-B22E-A9C3F8F3D58AQ38101603-C0FED499-9F3D-4E90-9FC6-4F0E7E85A3C1Q38176858-C32CA26B-ADC2-4CB4-801D-E3333AB4EB5DQ38709785-CE463791-081E-4214-AE93-F1FCF82A714FQ39110584-DC861385-0724-43F9-8F58-5B849A4F1219Q39406388-52DF11F9-3FC4-4EAA-9B3D-06D180749FA7Q39521848-79066CEF-21B2-4907-9FF4-F58A507F32BF
P2860
BRAF as a potential therapeutic target in melanoma and other malignancies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
BRAF as a potential therapeutic target in melanoma and other malignancies.
@ast
BRAF as a potential therapeutic target in melanoma and other malignancies.
@en
type
label
BRAF as a potential therapeutic target in melanoma and other malignancies.
@ast
BRAF as a potential therapeutic target in melanoma and other malignancies.
@en
prefLabel
BRAF as a potential therapeutic target in melanoma and other malignancies.
@ast
BRAF as a potential therapeutic target in melanoma and other malignancies.
@en
P1433
P1476
BRAF as a potential therapeutic target in melanoma and other malignancies.
@en
P2093
Barbara L Weber
P356
10.1016/S1535-6108(03)00189-2
P577
2003-08-01T00:00:00Z